There are currently 1271 clinical trials in Cleveland, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cleveland Clinic, Cleveland Clinic Foundation, Case Western Reserve University and University Hospitals Cleveland Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
NCT05918211
Recruiting
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
07/30/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Single Ventricle Heart Disease
Register for Updates
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483
Recruiting
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University Hospitals | UH Cleveland Medical Center - Department of Medicine - Rheumatology Division, Cleveland, Ohio
Conditions: Psoriatic Arthritis
Register for Updates
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171
Recruiting
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
Register for Updates
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
NCT06088290
Recruiting
The primary objective of this phase IIb/III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Cleveland Clinic Main Campus, Cleveland, Ohio
Conditions: Leiomyosarcoma
Register for Updates
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT04166409
Recruiting
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs... Read More
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
07/29/2025
Locations: Rainbow Babies and Childrens Hospital, Cleveland, Ohio
Conditions: Low Grade Glioma, Low Grade Astrocytoma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma
Register for Updates
VK2735 for Weight Management Phase 3
NCT07104500
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Viking Clinical Site #1044, Cleveland, Ohio
Conditions: Weight Loss
Register for Updates
Assessment of Coronary Microvascular Dysfunction After STEMI Using Continuous Saline Thermodilution
NCT06795035
Recruiting
The goal of this observational study to measure the heart's microvascular function in the setting of a myocardial infarction (MI), or heart attack, using a method called continuous saline thermodilution (CST). The participants will include people who are experiencing MI from sudden and complete blockage of a coronary artery requiring immediate balloon and/or stent therapy. After getting the balloon and/or stent therapy, participants will have their heart's microvascular system tested using CST.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: ST Elevation Myocardial Infarction, Coronary Microvascular Dysfunction, Microvascular Obstruction
Register for Updates
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927
Recruiting
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Viking Clinical Site #2044, Cleveland, Ohio
Conditions: Weight Loss
Register for Updates
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479
Recruiting
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Local Institution - 0193, Cleveland, Ohio
Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)
Register for Updates
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386
Recruiting
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio
Conditions: Non-small Cell Lung Cancer
Register for Updates
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755
Recruiting
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/29/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio +1 locations
Conditions: Moderate Aortic Valve Stenosis
Register for Updates